Tuesday, November 26, 2013 7:00 PM EST
Presenters: Jacquelyn Bainbridge, PharmD, FCCP,
and Sheldon J. Rich, RPh, PhD
This webcast will provide live credit (L) for those states requiring it.
Multiple sclerosis (MS) is a costly disease in terms of its effect on patients’ quality of life and its financial costs to society. Balancing cost-effective treatment with current guidelines and optimal therapy is a challenge to both managed care and specialty pharmacists. Additionally, the explosion in scientific knowledge over the last decade is overwhelming to both researchers and practitioners in the health professions, particularly those who manage patients with MS. New research promises to expand the armamentarium to include medications with novel mechanisms of actions and more tolerable routes of administration than frequent, self-injected therapy, or infused options. Oral and intravenous therapies with infrequent dosing requirements—albeit with risks not previously relevant to the MS therapy decision process—are available now, and more of these types of therapies will continue to become available in the future. The choice to start, stop, or change a drug has implications for healthcare insurers, managed care organizations, as well as healthcare providers. The cost of therapy has increasingly become a part of the neurology treatment delivery equation, and it is important that pharmacists consider this, as well as many other important factors, into their care of patients with MS.
This live webcast will provide the most current data on the management of MS thus allowing managed care and specialty pharmacists to improve patient and pharmacoeconomic outcomes.
- Activity Overview and Goals
- Multiple Sclerosis: Understanding the Nature of the Disease
Jacquelyn Bainbridge, PharmD, FCCP
- Optimizing Patient Outcomes with Current and Emerging Treatments
Jacquelyn Bainbridge, PharmD, FCCP
- Managed Care Considerations with Multiple Sclerosis Therapies
Sheldon J. Rich, RPh, PhD
- Specialty Pharmacy Considerations with Multiple Sclerosis Therapies
Sheldon J. Rich, RPh, PhD
This activity is designed for managed care and specialty pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- DISCUSS the mechanisms of action of treatment options and the importance of early and optimal management to slow disease progression.
- COMPARE agents for reducing disability and relapse rates and their effects on neurodegenerative and neuronal preservation processes.
- APPLY strategies to encourage patient adherence and minimize adverse events.
- EVALUATE pharmacoeconomic issues and current REMS associated with existing and emerging MS therapies, and the role of pharmacists in navigating the armamentarium of available treatments.
Jacquelyn Bainbridge, PharmD, FCCP (Co-Course Director)
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based program will provide a statement for 1.5 live contact hour credit (0.15 CEU). Successful completion includes participating in the activity, completing a self-assessment instrument, and completing an evaluation instrument. A statement of participation will be available online immediately following successful completion of the activity. ACPE Program Number: 0064-0000-13-216-L01-P.
Skaggs School of Pharmacy and Pharmaceutical Sciences
Department of Clinical Pharmacy and Department of Neurology
University of Colorado Anschutz Medical Campus
Sheldon J. Rich, RPh, PhD (Co-Course Director)
President – SJR Associates, LLC
Adjunct Clinical Assistant Professor – University of Michigan
Adjunct Assistant Professor – Wayne State University
Palm Beach Gardens, FL
Kevin Host, PharmD
Senior Vice President, Specialty Pharmacy
Overland Park, KS
Ellen Whipple Guthrie, PharmD
Clinical Assistant Professor
University of Georgia College of Pharmacy
Multiple Sclerosis Foundation
Fort Lauderdale, FL
Your CE credits will also be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions
regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website
(www.nabp.net/programs/cpe-monitor/cpe-monitor-service) or contact NABP Customer Service: email@example.com or telephone 847-391-4406.
NABP e-PROFILE ID NUMBER: To receive credit for your participation in this course, all pharmacists must include
their NABP e-Profile ID number, along with their date and month of birth on the last page of the evaluation form.
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.
The University of Tennessee College of Pharmacy fully complies
with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.